$WLDS
Wearable Devices Ltd. Stock $wlds

$wlds Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 20-F Financial Statement

#000121390024023073 Filed on March 15, 2024

Income Statement

Concept	2023 Q4	2023	2022
Revenue	$82.00K	$82.00K	$45.00K
YoY Change	82.22%	82.22%	-68.31%
Cost Of Revenue	$62.00K	$62.00K	$10.00K
YoY Change	520.0%	520.0%	0.0%
Gross Profit	$20.00K	$20.00K	$40.00K
YoY Change	-42.86%	-50.0%	-69.23%
Gross Profit Margin	24.39%	24.39%	88.89%
Selling, General & Admin	$4.890M	$4.890M	$3.318M
YoY Change	47.38%	47.38%	156.61%
% of Gross Profit	24450.0%	24450.0%	8295.0%
Research & Development	$3.316M	$3.316M	$2.271M
YoY Change	46.01%	46.01%	60.95%
% of Gross Profit	16580.0%	16580.0%	5677.5%
Depreciation & Amortization	$48.00K	$68.00K	$23.00K
YoY Change	140.0%	195.65%	109.09%
% of Gross Profit	240.0%	340.0%	57.5%
Operating Expenses	$8.206M	$8.206M	$5.589M
YoY Change	26.38%	46.82%	106.69%
Operating Profit	-$8.186M	-$8.186M	-$6.458M
YoY Change	26.76%	26.76%	141.96%
Interest Expense	$372.0K	$372.0K	-$40.00K
YoY Change	-1078.95%	-1030.0%	-166.67%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$7.814M	-$7.814M	-$6.500M
YoY Change	20.29%	20.22%	149.04%
Income Tax
% Of Pretax Income
Net Earnings	-$7.814M	-$7.814M	-$6.496M
YoY Change	20.29%	20.29%	148.51%
Net Earnings / Revenue	-9529.27%	-9529.27%	-14435.56%
Basic Earnings Per Share		-$0.48	-$0.53
Diluted Earnings Per Share	-$0.48	-$0.48	-$0.53
COMMON SHARES
Basic Shares Outstanding	20.39M shares	16.20M shares	12.28M shares
Diluted Shares Outstanding		16.20M shares	12.28M shares

Balance Sheet

Concept	2023 Q4	2023	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$4.855M	$4.855M	$10.37M
YoY Change	-53.18%	-53.18%	716.54%
Cash & Equivalents	$810.0K
Short-Term Investments	$4.045M	$4.045M
Other Short-Term Assets
YoY Change
Inventory	$1.032M	$1.032M	$10.00K
Prepaid Expenses
Receivables			$0.00
Other Receivables			$600.0K
Total Short-Term Assets	$6.752M	$6.752M	$10.98M
YoY Change	-38.48%	-38.51%	684.29%
LONG-TERM ASSETS
Property, Plant & Equipment	$194.0K	$786.0K	$250.0K
YoY Change	185.29%	214.4%	525.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$54.00K	$54.00K
YoY Change
Total Long-Term Assets	$840.0K	$840.0K	$240.0K
YoY Change	238.71%	250.0%	380.0%
TOTAL ASSETS
Total Short-Term Assets	$6.752M	$6.752M	$10.98M
Total Long-Term Assets	$840.0K	$840.0K	$240.0K
Total Assets	$7.592M	$7.592M	$11.22M
YoY Change	-32.36%	-32.34%	673.79%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$410.0K	$410.0K	$160.0K
YoY Change	162.82%	156.25%	128.57%
Accrued Expenses	$190.0K	$1.066M	$630.0K
YoY Change	31.03%	69.21%	133.33%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.788M	$1.788M	$1.150M
YoY Change	55.48%	55.48%	79.69%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$278.0K	$278.0K	$90.00K
YoY Change	208.89%	208.89%
Total Long-Term Liabilities	$278.0K	$278.0K	$90.00K
YoY Change	208.89%	208.89%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.788M	$1.788M	$1.150M
Total Long-Term Liabilities	$278.0K	$278.0K	$90.00K
Total Liabilities	$2.066M	$2.066M	$1.240M
YoY Change	66.08%	66.61%	93.75%
SHAREHOLDERS EQUITY
Retained Earnings	$21.20M
YoY Change	58.21%
Common Stock	$57.00K
YoY Change	32.56%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$5.526M	$5.526M	$9.980M
YoY Change
Total Liabilities & Shareholders Equity	$7.592M	$7.592M	$11.22M
YoY Change	-32.36%	-32.34%	673.79%

Cashflow Statement

Concept	2023 Q4	2023	2022
OPERATING ACTIVITIES
Net Income	-$7.814M	-$7.814M	-$6.496M
YoY Change	20.29%	20.29%	148.51%
Depreciation, Depletion And Amortization	$48.00K	$68.00K	$23.00K
YoY Change	140.0%	195.65%	109.09%
Cash From Operating Activities	-$4.714M	-$8.434M	-$5.714M
YoY Change	-17.44%	47.6%	171.71%
INVESTING ACTIVITIES
Capital Expenditures	$104.0K	$194.0K	$48.00K
YoY Change	108.0%	304.17%	33.33%
Acquisitions
YoY Change
Other Investing Activities	-$1.994M	-$4.054M	-$20.00K
YoY Change	9870.0%	20170.0%
Cash From Investing Activities	-$2.098M	-$4.248M	-$66.00K
YoY Change	2897.14%	6336.36%	83.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$2.000M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.669M	$3.119M	$14.88M
YoY Change	-88.78%	-79.04%	406.43%
NET CHANGE
Cash From Operating Activities	-4.714M	-$8.434M	-$5.714M
Cash From Investing Activities	-2.098M	-$4.248M	-$66.00K
Cash From Financing Activities	1.669M	$3.119M	$14.88M
Net Change In Cash	-5.143M	-$9.563M	$9.099M
YoY Change	-156.52%	-205.1%	1038.8%
FREE CASH FLOW
Cash From Operating Activities	-$4.714M	-$8.434M	-$5.714M
Capital Expenditures	$104.0K	$194.0K	$48.00K
Free Cash Flow	-$4.818M	-$8.628M	-$5.762M
YoY Change	-16.35%	49.74%	169.38%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16201238	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	12277224	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9709590	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	9709590	shares
CY2023	dei	Document Type DocumentType	20-F
CY2023	dei	Document Registration Statement DocumentRegistrationStatement	false
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Document Shell Company Report DocumentShellCompanyReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-41502
CY2023	dei	Entity Registrant Name EntityRegistrantName	Wearable Devices Ltd.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	L3
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	5 Ha-Tnufa Street
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Yokne’am Illit
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	2066736
CY2023	dei	Entity Address Country EntityAddressCountry	IL
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Israel
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	20387428	shares
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Document Accounting Standard DocumentAccountingStandard	U.S. GAAP
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023	dei	Auditor Firm AuditorFirmId	1185
CY2023	dei	Auditor Name AuditorName	Ziv Haft
CY2023	dei	Auditor Location AuditorLocation	Tel Aviv, Israel
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	810000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10373000	usd
CY2023Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	4045000	usd
CY2023Q4	us-gaap	Grants Receivable GrantsReceivable	108000	usd
CY2022Q4	us-gaap	Grants Receivable GrantsReceivable	54000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	757000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	543000	usd
CY2023Q4	us-gaap	Fifo Inventory Amount FIFOInventoryAmount	1032000	usd
CY2022Q4	us-gaap	Fifo Inventory Amount FIFOInventoryAmount	6000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	6752000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	10976000	usd
CY2023Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	54000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	592000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	180000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	194000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	68000	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	840000	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	248000	usd
CY2023Q4	us-gaap	Assets Assets	7592000	usd
CY2022Q4	us-gaap	Assets Assets	11224000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	410000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	156000	usd
CY2023Q4	wlds	Advance From Customers AdvanceFromCustomers	312000	usd
CY2022Q4	wlds	Advance From Customers AdvanceFromCustomers	353000	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	12000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	579000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	416000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	190000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	145000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	297000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	68000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1788000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1150000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	278000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	94000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	2066000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	1244000	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	20387428	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	20387428	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15049720	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15049720	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	57000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	43000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	26692000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	23346000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-21223000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-13409000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	5526000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	9980000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7592000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11224000	usd
CY2023	us-gaap	Revenues Revenues	82000	usd
CY2022	us-gaap	Revenues Revenues	45000	usd
CY2021	us-gaap	Revenues Revenues	142000	usd
CY2023	us-gaap	Cost Direct Material CostDirectMaterial	62000	usd
CY2022	us-gaap	Cost Direct Material CostDirectMaterial	10000	usd
CY2021	us-gaap	Cost Direct Material CostDirectMaterial	10000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3316000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2271000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1411000	usd
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2008000	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1370000	usd
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	665000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2882000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1948000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	628000	usd
CY2022	wlds	Prospective Initial Public Offering Expenses ProspectiveInitialPublicOfferingExpenses	904000	usd
CY2021	wlds	Prospective Initial Public Offering Expenses ProspectiveInitialPublicOfferingExpenses	97000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-8186000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-6458000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-2669000	usd
CY2023	wlds	Interest Expense And Exchange Rate InterestExpenseAndExchangeRate	372000	usd
CY2022	wlds	Interest Expense And Exchange Rate InterestExpenseAndExchangeRate	-38000	usd
CY2021	wlds	Interest Expense And Exchange Rate InterestExpenseAndExchangeRate	55000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-7814000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-6496000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-2614000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.48
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.53
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.27
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-2888000	usd
CY2021	wlds	Issuance Of Ordinary Shares And Warrants Net Of Issuance Cost IssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCost	2925000	usd
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	3072000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	299000	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1000	usd
CY2021	wlds	Stock Issued During Period Value Of Payment On Behalf Of Shares Issued StockIssuedDuringPeriodValueOfPaymentOnBehalfOfSharesIssued	12000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8434000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5714000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2614000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	807000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	807000	usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1600	usd
CY2022	wlds	Issuance Of Units Of Ordinary Shares And Warrants In Connection With The Initial Public Offering Net IssuanceOfUnitsOfOrdinarySharesAndWarrantsInConnectionWithTheInitialPublicOfferingNet	14319000	usd
CY2022	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	400000	usd
CY2022	wlds	Issuance Of Ordinary Shares As A Result Of Exercise Of Warrants IssuanceOfOrdinarySharesAsAResultOfExerciseOfWarrants	160000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	790000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6496000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	9980000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1670000	usd
CY2023	wlds	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	1449000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	241000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-7814000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	5526000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-7814000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-6496000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-2614000	usd
CY2023	us-gaap	Depreciation Depreciation	68000	usd
CY2022	us-gaap	Depreciation Depreciation	23000	usd
CY2021	us-gaap	Depreciation Depreciation	11000	usd
CY2021	wlds	Accrued Interest On Convertible Securities AccruedInterestOnConvertibleSecurities	20000	usd
CY2023	wlds	Accrued Interest On Deposits AccruedInterestOnDeposits	-45000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	241000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	790000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	299000	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	68000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-8000	usd
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	8000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1026000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-5000	usd
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-9000	usd
CY2023	wlds	Decreaseincrease In Governmental Grants Receivables DecreaseincreaseInGovernmentalGrantsReceivables	54000	usd
CY2022	wlds	Decreaseincrease In Governmental Grants Receivables DecreaseincreaseInGovernmentalGrantsReceivables	-8000	usd
CY2021	wlds	Decreaseincrease In Governmental Grants Receivables DecreaseincreaseInGovernmentalGrantsReceivables	11000	usd
CY2023	wlds	Increase In Other Receivables And Prepaid Expenses IncreaseInOtherReceivablesAndPrepaidExpenses	136000	usd
CY2022	wlds	Increase In Other Receivables And Prepaid Expenses IncreaseInOtherReceivablesAndPrepaidExpenses	496000	usd
CY2021	wlds	Increase In Other Receivables And Prepaid Expenses IncreaseInOtherReceivablesAndPrepaidExpenses	30000	usd
CY2023	wlds	Increase Decrease In Advance Payments IncreaseDecreaseInAdvancePayments	-41000	usd
CY2022	wlds	Increase Decrease In Advance Payments IncreaseDecreaseInAdvancePayments	79000	usd
CY2021	wlds	Increase Decrease In Advance Payments IncreaseDecreaseInAdvancePayments	63000	usd
CY2023	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-12000	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-12000	usd
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	9000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	254000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	84000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	40000	usd
CY2023	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	163000	usd
CY2022	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	194000	usd
CY2021	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	119000	usd
CY2021	wlds	Increase Decrease In Advance Payments On Governmental Grant IncreaseDecreaseInAdvancePaymentsOnGovernmentalGrant	42000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	36000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	99000	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	32000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2103000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	194000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	48000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	36000	usd
CY2023	us-gaap	Payments To Acquire Restricted Certificates Of Deposit PaymentsToAcquireRestrictedCertificatesOfDeposit	4054000	usd
CY2022	wlds	Prepayments Of Leasing PrepaymentsOfLeasing	18000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4248000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-66000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-36000	usd
CY2023	wlds	Proceeds From Issuance Of Shares Issued In The Public Offering Net Of Issuance Cost ProceedsFromIssuanceOfSharesIssuedInThePublicOfferingNetOfIssuanceCost	1670000	usd
CY2022	wlds	Proceeds From Issuance Of Units Of Ordinary Shares And Warrants In Connection With The Initial Publi ProceedsFromIssuanceOfUnitsOfOrdinarySharesAndWarrantsInConnectionWithTheInitialPubli	14319000	usd
CY2021	wlds	Proceeds From Issuance Of Ordinary Shares And Warrants Net Of Issuance Cost ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCost	2925000	usd
CY2022	wlds	Proceeds From Issuance Of Saf Es ProceedsFromIssuanceOfSAFEs	500000	usd
CY2022	wlds	Refund To Safe Investors RefundToSAFEInvestors	100000	usd
CY2022	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	800000	usd
CY2022	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	800000	usd
CY2022	wlds	Proceeds From Issuance Of Ordinary Shares As A Result Of Exercise Of Warrants ProceedsFromIssuanceOfOrdinarySharesAsAResultOfExerciseOfWarrants	160000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1000	usd
CY2021	wlds	Payment On Behalf Of Issued Shares PaymentOnBehalfOfIssuedShares	12000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3119000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14879000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2938000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-9563000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	9099000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	799000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10373000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1274000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	475000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	810000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10373000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1274000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	40000	usd
CY2023	wlds	Interest Received From Deposits InterestReceivedFromDeposits	-305000	usd
CY2022	wlds	Conversion Of Safe To Equity ConversionOfSAFEToEquity	400000	usd
CY2023	wlds	Rightof Use Asset Recognized Against Lease Liability RightofUseAssetRecognizedAgainstLeaseLiability	644000	usd
CY2022	wlds	Rightof Use Asset Recognized Against Lease Liability RightofUseAssetRecognizedAgainstLeaseLiability	229000	usd
CY2023	wlds	Annual Gross Revenues Exceed AnnualGrossRevenuesExceed	1235000000	usd
CY2023	wlds	Ordinary Shares Warrants Held By Nonaffiliates OrdinarySharesWarrantsHeldByNonaffiliates	700000000	usd
CY2023	wlds	Nonconvertible Debt Securities NonconvertibleDebtSecurities	1000000000	usd
CY2022Q3	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	13300000	usd
	wlds	Net Proceeds From Issuance Secondary Public Offering NetProceedsFromIssuanceSecondaryPublicOffering	1700000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	21200000	usd
CY2022Q3	wlds	Warrants Exercise Into Ordinary Shares WarrantsExerciseIntoOrdinaryShares	40000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	40000	shares
CY2023	wlds	Gross Proceeds GrossProceeds	16000000	usd
CY2023	wlds	Underwriting Net Proceed UnderwritingNetProceed	14900000	usd
CY2023	wlds	Underwriting Discounts And Commissions UnderwritingDiscountsAndCommissions	1100000	usd
CY2023Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	4444444	shares
CY2023Q4	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2000000	usd
CY2023Q4	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	1700000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>b.</b></span></td> <td style="padding-right: 3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use of estimates</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 54pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, as well as to disclose contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting years. On an ongoing basis, management evaluates its estimates, judgments and assumptions. Management bases its estimates, judgments and assumptions on historical experience and on various other factors that are believed to be reasonable under the circumstances. Actual results could differ from those estimates.</span></p>
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	514000	usd
CY2023Q4	us-gaap	Lessee Finance Lease Renewal Term1 LesseeFinanceLeaseRenewalTerm1	P12M
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	6000	usd
CY2023Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	206000	usd
CY2023	wlds	Rate Of Monthly Severance Percentage RateOfMonthlySeverancePercentage	0.0833	pure
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	312000	usd
CY2023Q4	us-gaap	Fifo Inventory Amount FIFOInventoryAmount	1032000	usd
CY2022Q4	us-gaap	Fifo Inventory Amount FIFOInventoryAmount	6000	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>r.</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Concentration of Credit Risk</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company maintains certain cash balances in a well-known Israeli banks and a U.S.-based bank.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company’s labor expenses are denominated mainly in NIS, and therefore, subject to foreign currency risk. During the year ended December 31, 2023, the Company partially hedged its foreign currency exchange risk.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company’s derivative instruments primarily include foreign currency forward agreements related to the NIS and associated with certain payroll payments. The Company’s foreign currency forward agreements related to foreign currency balance sheet exposure provide economic hedges but are not designated as hedges for accounting purposes. Changes in the value of the derivative, along with the transaction gain or loss on the hedged item, are recorded within the Company’s consolidated statements of loss.</p>
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	334000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	140000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	140000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	72000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	194000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	68000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P2Y
CY2023	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	2 years
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	592000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	180000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	297000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	68000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	278000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	94000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	575000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	162000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	308000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	289000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	22000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	619000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	44000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	575000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	297000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	278000	usd
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	232000	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	74000	usd
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	42000	usd
CY2023	wlds	Grants Received Equal Percentage Rate GrantsReceivedEqualPercentageRate	1	pure
CY2023	wlds	Annual Alternative Interest Percentage AnnualAlternativeInterestPercentage	0.0071513	pure
CY2023	wlds	Fixed Annual Interest Rate FixedAnnualInterestRate	0.04	pure
CY2018Q4	wlds	Amounts Received Aggregate Amount AmountsReceivedAggregateAmount	1224000	usd
CY2021Q3	wlds	Amounts Received Aggregate Amount AmountsReceivedAggregateAmount	627000	usd
CY2023Q1	wlds	Amount Of Development Program AmountOfDevelopmentProgram	900000	usd
CY2023Q1	wlds	Amount Of Development Program AmountOfDevelopmentProgram	3100000	ils
CY2023Q4	wlds	Percentage Of Financing PercentageOfFinancing	0.60	pure
CY2023	wlds	Total Cash Received From The Iia TotalCashReceivedFromTheIIA	288000	usd
CY2023	wlds	Except Transfer Production Right ExceptTransferProductionRight	0.10	pure
CY2023	wlds	Production Transferred ProductionTransferred	0.10	pure
CY2023	wlds	Pay Increased Royalties Description PayIncreasedRoyaltiesDescription	the Company would be required to pay increased royalties, which usually amount to 1% in addition to the standard royalties rate 3%-3.5%, and also the total amount of its liability to the IIA may be increased to between 120% and 300% of the grants received from the IIA, depending on the manufacturing volume that is performed outside Israel (less royalties already paid to IIA).
CY2023	wlds	Marketing Grant Received MarketingGrantReceived	1	pure
CY2023Q4	us-gaap	Grants Receivable Current GrantsReceivableCurrent	95000	usd
CY2023	us-gaap	Lease Cost LeaseCost	5000	usd
	wlds	Lease Payment Increased LeasePaymentIncreased	0.10	pure
CY2017	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	400000	usd
CY2018	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	600000	usd
CY2019Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	100000	usd
CY2019Q2	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	200000	usd
CY2019Q4	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	100000	usd
CY2023	wlds	Convertible Security Description ConvertibleSecurityDescription	The beneficial conversion feature of each one of convertible security was valued at zero.
CY2022Q2	wlds	Cash Payment CashPayment	300000	usd
CY2022Q2	wlds	Premoney Valuation Amount PremoneyValuationAmount	26400000	usd
CY2021Q2	wlds	Warrant Price Per Share Percentage WarrantPricePerSharePercentage	0.80	pure
CY2021Q2	wlds	Purchase Price Per Share PurchasePricePerShare	2.25
CY2021Q2	wlds	Purchase Price Per Share PurchasePricePerShare	2.25
CY2022Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2
CY2022Q3	us-gaap	Other Borrowings OtherBorrowings	800000	usd
CY2023Q4	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	1000000	usd
CY2022Q3	wlds	Aggregate Amount AggregateAmount	800000	usd
CY2022Q3	us-gaap	Line Of Credit Facility Interest Rate At Period End LineOfCreditFacilityInterestRateAtPeriodEnd	0.04	pure
CY2023	wlds	Expense On Service Rendering ExpenseOnServiceRendering	420000	usd
CY2022	wlds	Expense On Service Rendering ExpenseOnServiceRendering	122000	usd
CY2021Q2	wlds	Ordinary Shares Warrant Exercisable OrdinarySharesWarrantExercisable	671687	shares
CY2022	wlds	Saf Es Amount SAFEsAmount	500000	usd
CY2022	wlds	Investor Investor	5
CY2022	wlds	Investor Amount InvestorAmount	100000	usd
CY2022	wlds	Converted Amount ConvertedAmount	400000	usd
CY2022Q4	wlds	Converted To Ordinary Shares ConvertedToOrdinaryShares	118204	shares
CY2022Q4	us-gaap	Cash Cash	100000	usd
CY2022Q4	us-gaap	Temporary Equity Aggregate Amount Of Redemption Requirement TemporaryEquityAggregateAmountOfRedemptionRequirement	25000	usd
CY2022Q3	wlds	Investors Exercised Warrants InvestorsExercisedWarrants	40000	shares
CY2022Q4	wlds	Employee Exercised Warrants EmployeeExercisedWarrants	4666	shares
CY2023Q2	wlds	Exercisable Warrants To Shares ExercisableWarrantsToShares	724139	shares
CY2023Q2	wlds	Stock Issued During Period Shares Exercise Of Warrants StockIssuedDuringPeriodSharesExerciseOfWarrants	724139	shares
CY2023Q2	wlds	Exercise Price Per Share ExercisePricePerShare	2
CY2023Q4	wlds	Proceeds From Issuance Follow On Public Offering ProceedsFromIssuanceFollowOnPublicOffering	2000000	usd
CY2023Q4	wlds	Ordinary Shares Issued OrdinarySharesIssued	4444444	shares
CY2023Q4	wlds	Ordinary Share Per Value OrdinarySharePerValue	0.45
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	1832805	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	988264	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.563
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	863264	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.614
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	471500	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.224
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	145000	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.184
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	4666	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.003
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	5000	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.664
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	15334	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.003
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1454764	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	0.777
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	988264	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	0.563
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	889125	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	0.612
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	753236	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	0.703
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.224
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	184
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.323
CY2022Q1	wlds	Termination Period TerminationPeriod	P10Y
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P90D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.55	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.041	pure
CY2023	wlds	Share Based Compensation Arrangement By Share Based Payment Award Expected Life Of Options ShareBasedCompensationArrangementByShareBasedPaymentAwardExpectedLifeOfOptions	P6Y3M
CY2023	wlds	Exercise Price Per Share ExercisePricePerShare	1.32
CY2023	wlds	Termination Period TerminationPeriod	P10Y
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P90D
CY2023	wlds	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Option Grant Date ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOptionGrantDate	0.12
CY2023	wlds	Options Expenses OptionsExpenses	15000	usd
CY2023	wlds	Vesting Periods VestingPeriods	P3Y
CY2023Q2	wlds	Issuance Of Shares Options IssuanceOfSharesOptions	100000	shares
CY2023Q2	wlds	Exercise Price Per Share ExercisePricePerShare	0.55
CY2023Q2	wlds	Termination Period TerminationPeriod	P10Y
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P90D
CY2023Q2	wlds	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Option Grant Date ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOptionGrantDate	0.26
CY2023Q2	wlds	Options Expenses OptionsExpenses	26000	usd
CY2023Q2	wlds	Vesting Periods VestingPeriods	P3Y
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	241000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	790000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	299000	usd
CY2023Q4	wlds	Exercise Price Of Warrants ExercisePriceOfWarrants	4
CY2023	wlds	Warrant Be Reduced To An Exercise Price Percentage WarrantBeReducedToAnExercisePricePercentage	0.50	pure
CY2023	wlds	Initial Exercise Price Percentage InitialExercisePricePercentage	0.50	pure
CY2023	wlds	Weighted Average Price Percentage WeightedAveragePricePercentage	1	pure
CY2023Q4	wlds	Lowest Reset Price LowestResetPrice	2
CY2023	wlds	Initial Exercise Prices Percentage InitialExercisePricesPercentage	0.50	pure
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	13800000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	3200000	usd
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022Q1	wlds	Officer Employee Monthly Salary OfficerEmployeeMonthlySalary	70000	ils
CY2022Q1	wlds	Related Party Monthly Salary RelatedPartyMonthlySalary	19000	usd
CY2022Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent		usd
CY2022Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent		usd
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023	wlds	Prospective Initial Public Offering Expenses ProspectiveInitialPublicOfferingExpenses		usd
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.27
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.48
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.53
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	12277224	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16201238	shares
CY2021	wlds	Conversion Of Ordinary A Shares To Ordinary Shares Value ConversionOfOrdinaryASharesToOrdinarySharesValue		usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised		usd
CY2023	wlds	Accrued Interest On Convertible Securities AccruedInterestOnConvertibleSecurities		usd
CY2022	wlds	Accrued Interest On Convertible Securities AccruedInterestOnConvertibleSecurities		usd
CY2022	wlds	Accrued Interest On Deposits AccruedInterestOnDeposits		usd
CY2021	wlds	Accrued Interest On Deposits AccruedInterestOnDeposits		usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized		usd
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized		usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable		usd
CY2023	wlds	Increase Decrease In Advance Payments On Governmental Grant IncreaseDecreaseInAdvancePaymentsOnGovernmentalGrant		usd
CY2022	wlds	Increase Decrease In Advance Payments On Governmental Grant IncreaseDecreaseInAdvancePaymentsOnGovernmentalGrant		usd
CY2022	us-gaap	Payments To Acquire Restricted Certificates Of Deposit PaymentsToAcquireRestrictedCertificatesOfDeposit		usd
CY2021	us-gaap	Payments To Acquire Restricted Certificates Of Deposit PaymentsToAcquireRestrictedCertificatesOfDeposit		usd
CY2023	wlds	Prepayments Of Leasing PrepaymentsOfLeasing		usd
CY2021	wlds	Prepayments Of Leasing PrepaymentsOfLeasing		usd
CY2022	wlds	Proceeds From Issuance Of Shares Issued In The Public Offering Net Of Issuance Cost ProceedsFromIssuanceOfSharesIssuedInThePublicOfferingNetOfIssuanceCost		usd
CY2021	wlds	Proceeds From Issuance Of Shares Issued In The Public Offering Net Of Issuance Cost ProceedsFromIssuanceOfSharesIssuedInThePublicOfferingNetOfIssuanceCost		usd
CY2023	wlds	Proceeds From Issuance Of Units Of Ordinary Shares And Warrants In Connection With The Initial Publi ProceedsFromIssuanceOfUnitsOfOrdinarySharesAndWarrantsInConnectionWithTheInitialPubli		usd
CY2021	wlds	Proceeds From Issuance Of Units Of Ordinary Shares And Warrants In Connection With The Initial Publi ProceedsFromIssuanceOfUnitsOfOrdinarySharesAndWarrantsInConnectionWithTheInitialPubli		usd
CY2023	wlds	Proceeds From Issuance Of Ordinary Shares And Warrants Net Of Issuance Cost ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCost		usd
CY2022	wlds	Proceeds From Issuance Of Ordinary Shares And Warrants Net Of Issuance Cost ProceedsFromIssuanceOfOrdinarySharesAndWarrantsNetOfIssuanceCost		usd
CY2023	wlds	Proceeds From Issuance Of Saf Es ProceedsFromIssuanceOfSAFEs		usd
CY2021	wlds	Proceeds From Issuance Of Saf Es ProceedsFromIssuanceOfSAFEs		usd
CY2023	wlds	Refund To Safe Investors RefundToSAFEInvestors		usd
CY2021	wlds	Refund To Safe Investors RefundToSAFEInvestors		usd
CY2023	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit		usd
CY2021	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit		usd
CY2023	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit		usd
CY2021	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit		usd
CY2023	wlds	Proceeds From Issuance Of Ordinary Shares As A Result Of Exercise Of Warrants ProceedsFromIssuanceOfOrdinarySharesAsAResultOfExerciseOfWarrants	1449000	usd
CY2021	wlds	Proceeds From Issuance Of Ordinary Shares As A Result Of Exercise Of Warrants ProceedsFromIssuanceOfOrdinarySharesAsAResultOfExerciseOfWarrants		usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2023	wlds	Payment On Behalf Of Issued Shares PaymentOnBehalfOfIssuedShares		usd
CY2022	wlds	Payment On Behalf Of Issued Shares PaymentOnBehalfOfIssuedShares		usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2022	wlds	Interest Received From Deposits InterestReceivedFromDeposits		usd
CY2021	wlds	Interest Received From Deposits InterestReceivedFromDeposits		usd
CY2023	wlds	Conversion Of Safe To Equity ConversionOfSAFEToEquity		usd
CY2021	wlds	Conversion Of Safe To Equity ConversionOfSAFEToEquity		usd
CY2021	wlds	Rightof Use Asset Recognized Against Lease Liability RightofUseAssetRecognizedAgainstLeaseLiability		usd
CY2022Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves		usd
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves		usd
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2023Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P2Y
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001887673

Files In Submission

Name	View Source	Status
0001213900-24-023073-index-headers.html	Edgar Link	pending
0001213900-24-023073-index.html	Edgar Link	pending
0001213900-24-023073.txt	Edgar Link	pending
0001213900-24-023073-xbrl.zip	Edgar Link	pending
ea0200952-20f_wearable.htm	Edgar Link	pending
ea020095201ex12-1_wearable.htm	Edgar Link	pending
ea020095201ex12-2_wearable.htm	Edgar Link	pending
ea020095201ex13-1_wearable.htm	Edgar Link	pending
ea020095201ex13-2_wearable.htm	Edgar Link	pending
ea020095201ex15-1_wearable.htm	Edgar Link	pending
ea020095201ex2-3_wearable.htm	Edgar Link	pending
ea020095201ex97-1_wearable.htm	Edgar Link	pending
ex15-1_001.jpg	Edgar Link	pending
ex15-1_002.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
image_003.jpg	Edgar Link	pending
image_004.jpg	Edgar Link	pending
image_005.jpg	Edgar Link	pending
image_006.jpg	Edgar Link	pending
image_007.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
ea0200952-20f_wearable_htm.xml	Edgar Link	completed
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
wlds-20231231.xsd	Edgar Link	pending
wlds-20231231_def.xml	Edgar Link	unprocessable
wlds-20231231_lab.xml	Edgar Link	unprocessable
wlds-20231231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
wlds-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$WLDS
Wearable Devices Ltd. Stock $wlds

2023 Q4 Form 20-F Financial Statement

#000121390024023073 Filed on March 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$WLDS Wearable Devices Ltd. Stock $wlds

2023 Q4 Form 20-F Financial Statement

#000121390024023073 Filed on March 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$WLDS
Wearable Devices Ltd. Stock $wlds